TTR time to colorectal cancer recurrence, OS overall survival, HR hazard ratio, 95% CI 95% confidence interval, pT pathological tumour (T) stage, MMR DNA mismatch repair, MMR-P mismatch repair proficient, MMR-D mismatch repair deficient, POLE-mutant pathogenic POLE exonuclease domain mutation. This evidence concerns the gene POLE and colorectal cancer.